Oculis Advances Non-Invasive DME Treatment Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy OCS?
Source: Newsfilter
- Current Treatment Landscape: Diabetic macular edema (DME) primarily affects individuals around the age of 52, with 60% of patients remaining untreated one year post-diagnosis, indicating significant gaps in current treatment approaches that hinder vision recovery opportunities.
- DME AWARE Findings: The DME AWARE Delphi study underscores the critical need for non-invasive treatment options, with experts reaching consensus on prioritizing eye drops for early intervention to improve visual function and reduce inflammatory factors.
- Potential of OCS-01: Oculis's OCS-01 eye drops are in Phase 3 trials and, if successful, could become the first non-invasive treatment for DME, offering a new option for the 40% of patients who inadequately respond to existing injection therapies.
- Global Expert Consensus: The DME AWARE study, involving 25 leading retina and ophthalmology experts, established a global consensus on the urgent need for non-invasive therapies and early intervention in DME management, potentially driving transformative changes in future clinical practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCS
Wall Street analysts forecast OCS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.090
Low
29.00
Averages
40.00
High
55.00
Current: 31.090
Low
29.00
Averages
40.00
High
55.00
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oculis Secures FDA Special Protocol Assessment for Privosegtor
- FDA Agreement Confirmation: Oculis has secured a Special Protocol Assessment (SPA) from the FDA, confirming that the design of the PIONEER-1 trial meets the requirements for a future NDA submission, paving the way for Privosegtor's registration in treating optic neuritis and highlighting the company's strategic potential in neuroprotection.
- Clinical Trial Progress: The PIONEER-1 trial, as the first registrational study for Privosegtor, will evaluate its efficacy in patients with optic neuritis, with a primary endpoint of significant improvement in low-contrast visual acuity at three months, which is expected to provide robust data for future market launch.
- Significant Market Opportunity: Privosegtor is poised to become the first neuroprotective therapy for optic neuritis, with Riad Sherif noting a potential $7 billion market in acute optic neuropathies in the U.S., underscoring Oculis's strategic importance in addressing unmet medical needs.
- Positive Clinical Outcomes: In the prior ACUITY trial, Privosegtor combined with steroids demonstrated significant vision improvement without serious adverse events, laying the groundwork for its Breakthrough Therapy designation from the FDA and PRIME designation from the EMA, further enhancing its market competitiveness.
See More
Oculis Advances Non-Invasive DME Treatment Options
- Current Treatment Landscape: Diabetic macular edema (DME) primarily affects individuals around the age of 52, with 60% of patients remaining untreated one year post-diagnosis, indicating significant gaps in current treatment approaches that hinder vision recovery opportunities.
- DME AWARE Findings: The DME AWARE Delphi study underscores the critical need for non-invasive treatment options, with experts reaching consensus on prioritizing eye drops for early intervention to improve visual function and reduce inflammatory factors.
- Potential of OCS-01: Oculis's OCS-01 eye drops are in Phase 3 trials and, if successful, could become the first non-invasive treatment for DME, offering a new option for the 40% of patients who inadequately respond to existing injection therapies.
- Global Expert Consensus: The DME AWARE study, involving 25 leading retina and ophthalmology experts, established a global consensus on the urgent need for non-invasive therapies and early intervention in DME management, potentially driving transformative changes in future clinical practices.
See More
Oculis Highlights DME Management Study Findings
- Study Findings Presentation: Oculis will present the latest findings from the DME AWARE Delphi study at the 2026 ARVO Annual Meeting, emphasizing the urgent need for non-invasive treatment options to enhance care for diabetic macular edema patients.
- Clinical Progress Update: CEO Riad Sherif announced that the final patient visit for the Phase 3 DIAMOND study of OCS-01 eye drops has been completed, with pivotal topline results expected in June 2026, potentially redefining treatment paradigms for diabetic macular edema.
- Privosegtor's Potential: The Phase 2 ACUITY trial of Privosegtor in patients with acute optic neuritis demonstrated neuroprotective effects, indicating its potential to become the first neuroprotective therapy for optic neuritis, with broad applicability in other neuro-ophthalmic diseases.
- Global Impact: Oculis' research and product development not only target diabetic macular edema but also encompass other neuro-ophthalmic conditions, highlighting the company's strategic importance in addressing significant unmet medical needs worldwide.
See More
Oculis Completes Final Patient Visit in Phase 3 DIAMOND Program for OCS-01
- Clinical Trial Progress: Oculis Holding AG announced the completion of the final patient visit in the Phase 3 DIAMOND program for OCS-01, with topline results expected in June 2026, marking a significant advancement in the treatment of diabetic macular edema.
- Patient Recruitment: The DIAMOND program consists of two randomized, double-masked, multicenter trials, enrolling over 800 patients who were randomized to receive either OCS-01 or a vehicle, demonstrating the company's extensive engagement in clinical research and commitment to patient needs.
- Market Potential Analysis: In the U.S., approximately 1.8 million people are diagnosed with diabetic macular edema, with about 1 million remaining untreated, indicating a substantial market opportunity for Oculis to address the underserved patient population.
- Strong Financial Position: As of December 31, Oculis reported $268.7 million in cash and short-term investments, with an expected cash runway extending into 2029, reflecting the company's financial stability for ongoing research and market initiatives.
See More
Completion of OCS-01 Trials Marks Key Milestone Ahead of 2026 Results
- Trial Completion: The final patient visit for OCS-01's DIAMOND program, involving over 800 patients, has been completed, with topline results expected in June 2026, marking a significant advancement in the treatment of diabetic macular edema (DME) and potentially transforming existing treatment paradigms.
- Significant Market Need: In the U.S., approximately 1 million DME patients remain untreated, highlighting the urgent demand for early intervention and new therapies; OCS-01, as the first non-invasive topical treatment, could fill this market gap, with an estimated market size of $3 billion.
- Efficacy Demonstrated: In the first stage of the DIAMOND program, OCS-01 showed significant improvements in visual acuity and rapid edema reduction, further validating its potential as a treatment for DME, particularly for patients inadequately served by current therapies.
- Future Development Outlook: Oculis plans to submit a New Drug Application (NDA) in Q4 2026 and continues to advance other clinical projects, indicating the company's commitment to addressing significant unmet medical needs in the ophthalmology sector.
See More
Oculis Announces 2026 Investor Conference Participation and Key Updates
- Clinical Trial Progress: Oculis's OCS-01 is on track to release pivotal Phase 3 trial results for diabetic macular edema (DME) in June 2026, which will solidify the company's leadership position in the ophthalmology sector.
- Precision Medicine Innovation: Licaminlimab is being evaluated as the first genotype-based development program for dry eye disease (DED), with topline results expected by late 2026, marking a significant breakthrough in precision medicine that could transform treatment paradigms for DED.
- Market Opportunity: Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA for optic neuritis (ON), advancing its registrational program with a potential market opportunity exceeding $7 billion in the U.S., highlighting Oculis's substantial market potential in neuro-ophthalmology.
- Financial Robustness: With a strong balance sheet and a rich clinical pipeline, Oculis is positioned to deliver six pivotal readouts with current funding, further advancing its mission to innovate in eye care and neuro-ophthalmology.
See More
Oculis Secures FDA Special Protocol Assessment for Privosegtor
- FDA Agreement Confirmation: Oculis has secured a Special Protocol Assessment (SPA) from the FDA, confirming that the design of the PIONEER-1 trial meets the requirements for a future NDA submission, paving the way for Privosegtor's registration in treating optic neuritis and highlighting the company's strategic potential in neuroprotection.
- Clinical Trial Progress: The PIONEER-1 trial, as the first registrational study for Privosegtor, will evaluate its efficacy in patients with optic neuritis, with a primary endpoint of significant improvement in low-contrast visual acuity at three months, which is expected to provide robust data for future market launch.
- Significant Market Opportunity: Privosegtor is poised to become the first neuroprotective therapy for optic neuritis, with Riad Sherif noting a potential $7 billion market in acute optic neuropathies in the U.S., underscoring Oculis's strategic importance in addressing unmet medical needs.
- Positive Clinical Outcomes: In the prior ACUITY trial, Privosegtor combined with steroids demonstrated significant vision improvement without serious adverse events, laying the groundwork for its Breakthrough Therapy designation from the FDA and PRIME designation from the EMA, further enhancing its market competitiveness.
See More
Oculis Advances Non-Invasive DME Treatment Options
- Current Treatment Landscape: Diabetic macular edema (DME) primarily affects individuals around the age of 52, with 60% of patients remaining untreated one year post-diagnosis, indicating significant gaps in current treatment approaches that hinder vision recovery opportunities.
- DME AWARE Findings: The DME AWARE Delphi study underscores the critical need for non-invasive treatment options, with experts reaching consensus on prioritizing eye drops for early intervention to improve visual function and reduce inflammatory factors.
- Potential of OCS-01: Oculis's OCS-01 eye drops are in Phase 3 trials and, if successful, could become the first non-invasive treatment for DME, offering a new option for the 40% of patients who inadequately respond to existing injection therapies.
- Global Expert Consensus: The DME AWARE study, involving 25 leading retina and ophthalmology experts, established a global consensus on the urgent need for non-invasive therapies and early intervention in DME management, potentially driving transformative changes in future clinical practices.
See More
Oculis Highlights DME Management Study Findings
- Study Findings Presentation: Oculis will present the latest findings from the DME AWARE Delphi study at the 2026 ARVO Annual Meeting, emphasizing the urgent need for non-invasive treatment options to enhance care for diabetic macular edema patients.
- Clinical Progress Update: CEO Riad Sherif announced that the final patient visit for the Phase 3 DIAMOND study of OCS-01 eye drops has been completed, with pivotal topline results expected in June 2026, potentially redefining treatment paradigms for diabetic macular edema.
- Privosegtor's Potential: The Phase 2 ACUITY trial of Privosegtor in patients with acute optic neuritis demonstrated neuroprotective effects, indicating its potential to become the first neuroprotective therapy for optic neuritis, with broad applicability in other neuro-ophthalmic diseases.
- Global Impact: Oculis' research and product development not only target diabetic macular edema but also encompass other neuro-ophthalmic conditions, highlighting the company's strategic importance in addressing significant unmet medical needs worldwide.
See More
Oculis Completes Final Patient Visit in Phase 3 DIAMOND Program for OCS-01
- Clinical Trial Progress: Oculis Holding AG announced the completion of the final patient visit in the Phase 3 DIAMOND program for OCS-01, with topline results expected in June 2026, marking a significant advancement in the treatment of diabetic macular edema.
- Patient Recruitment: The DIAMOND program consists of two randomized, double-masked, multicenter trials, enrolling over 800 patients who were randomized to receive either OCS-01 or a vehicle, demonstrating the company's extensive engagement in clinical research and commitment to patient needs.
- Market Potential Analysis: In the U.S., approximately 1.8 million people are diagnosed with diabetic macular edema, with about 1 million remaining untreated, indicating a substantial market opportunity for Oculis to address the underserved patient population.
- Strong Financial Position: As of December 31, Oculis reported $268.7 million in cash and short-term investments, with an expected cash runway extending into 2029, reflecting the company's financial stability for ongoing research and market initiatives.
See More
Completion of OCS-01 Trials Marks Key Milestone Ahead of 2026 Results
- Trial Completion: The final patient visit for OCS-01's DIAMOND program, involving over 800 patients, has been completed, with topline results expected in June 2026, marking a significant advancement in the treatment of diabetic macular edema (DME) and potentially transforming existing treatment paradigms.
- Significant Market Need: In the U.S., approximately 1 million DME patients remain untreated, highlighting the urgent demand for early intervention and new therapies; OCS-01, as the first non-invasive topical treatment, could fill this market gap, with an estimated market size of $3 billion.
- Efficacy Demonstrated: In the first stage of the DIAMOND program, OCS-01 showed significant improvements in visual acuity and rapid edema reduction, further validating its potential as a treatment for DME, particularly for patients inadequately served by current therapies.
- Future Development Outlook: Oculis plans to submit a New Drug Application (NDA) in Q4 2026 and continues to advance other clinical projects, indicating the company's commitment to addressing significant unmet medical needs in the ophthalmology sector.
See More
Oculis Announces 2026 Investor Conference Participation and Key Updates
- Clinical Trial Progress: Oculis's OCS-01 is on track to release pivotal Phase 3 trial results for diabetic macular edema (DME) in June 2026, which will solidify the company's leadership position in the ophthalmology sector.
- Precision Medicine Innovation: Licaminlimab is being evaluated as the first genotype-based development program for dry eye disease (DED), with topline results expected by late 2026, marking a significant breakthrough in precision medicine that could transform treatment paradigms for DED.
- Market Opportunity: Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA for optic neuritis (ON), advancing its registrational program with a potential market opportunity exceeding $7 billion in the U.S., highlighting Oculis's substantial market potential in neuro-ophthalmology.
- Financial Robustness: With a strong balance sheet and a rich clinical pipeline, Oculis is positioned to deliver six pivotal readouts with current funding, further advancing its mission to innovate in eye care and neuro-ophthalmology.
See More
